{
  "first_published_at": "2013-11-14", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON336722", 
  "title": "Cabazitaxel (Jevtana▼): risk of medication error resulting in overdose—ensure entire contents of solvent vial is added to concentrate vial ", 
  "tags": "{\"parsed_therapeutic\": [\"cancer\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Cancer\"]}", 
  "_document_number": 49, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/dose_icon.png", 
  "therapeutic_area": [
    "cancer"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Cabazitaxel (Jevtana&#9660;): risk of medication error resulting in overdose&#8212;ensure entire contents of solvent vial is added to concentrate vial </h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: November 2013</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br><p>Cabazitaxel is supplied as a vial of concentrate and a vial of solvent. The concentrate must first be diluted with the solvent supplied before adding to the infusion solution</p>\n\n<p>It is essential that the <strong>entire</strong> <strong>contents</strong> of the solvent vial is added to the concentrate vial to produce a concentrate-solvent mixture with the intended concentration of 10&#160;mg/mL cabazitaxel</p>\n\n<p>Pharmacies should review worksheets used in the preparation of cabazitaxel to ensure that they inform pharmacy staff to add the entire contents of the solvent vial to the concentrate vial&#160;</p><br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p><strong>Background</strong></p>\n\n<p>Cabazitaxel (Jevtana<strong>&#9660;</strong>) in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.</p>\n\n<p>There have been reports of medication error that have occurred because the entire fill volume of the solvent vial was not added to the concentrate vial. This has resulted in some patients receiving a higher dose (15&#8211;20% higher) of cabazitaxel than was intended.</p>\n\n<p>The solvent vial and the concentrate vial each contain an overfill to compensate for liquid lost during the initial dilution process. Therefore, the <u>entire</u> contents of the solvent vial must be added to the concentrate vial to ensure that the resulting concentrate-solvent mixture contains the intended concentration of 10&#160;mg/mL cabazitaxel and has a minimal extractable volume of 6 mL.</p>\n\n<p>The required volume of the concentrate-solvent mixture should be diluted immediately (within 1 hour) to prepare the solution for infusion, as described in the <a target=\"_blank\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002018/human_med_001428.jsp&#38;mid=WC0b01ac058001d124\">Summary of Product Characteristics</a>, which should be consulted before preparing the cabazitaxel solution for infusion.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>All healthcare professionals involved in the preparation of cabazitaxel solution for infusion should be aware that the entire contents of the solvent vial must be added to the concentrate vial to produce a concentrate-solvent mixture with the intended concentration of 10&#160;mg/mL cabazitaxel</li>\n\n<li>Pharmacists should review worksheets that are used in the preparation of cabazitaxel to ensure that they correctly inform pharmacy staff to add the entire content of the solvent vial to the concentrate vial</li>\n\n<li>Please report suspected adverse reactions, including those related to medication error, occurring with cabazitaxel on a Yellow Card (<a href=\"http://www.mhra.gov.uk/yellowcard\">www.mhra.gov.uk/yellowcard</a>) &#160;</li>\n</ul>\n</div>\n\n<p><strong>Further information</strong></p>\n\n<p>Letter sent to healthcare professionals <a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON333631\">sent Oct 23, 2013</a></p>\n\n<p><em>Article citation: Drug Safety Update volume 7 issue 4, November 2013: A4.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p><strong>Background</strong></p>\n\n<p>Cabazitaxel (Jevtana<strong>&#9660;</strong>) in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.</p>\n\n<p>There have been reports of medication error that have occurred because the entire fill volume of the solvent vial was not added to the concentrate vial. This has resulted in some patients receiving a higher dose (15&#8211;20% higher) of cabazitaxel than was intended.</p>\n\n<p>The solvent vial and the concentrate vial each contain an overfill to compensate for liquid lost during the initial dilution process. Therefore, the <u>entire</u> contents of the solvent vial must be added to the concentrate vial to ensure that the resulting concentrate-solvent mixture contains the intended concentration of 10&#160;mg/mL cabazitaxel and has a minimal extractable volume of 6 mL.</p>\n\n<p>The required volume of the concentrate-solvent mixture should be diluted immediately (within 1 hour) to prepare the solution for infusion, as described in the <a target=\"_blank\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002018/human_med_001428.jsp&amp;mid=WC0b01ac058001d124\">Summary of Product Characteristics</a>, which should be consulted before preparing the cabazitaxel solution for infusion.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>All healthcare professionals involved in the preparation of cabazitaxel solution for infusion should be aware that the entire contents of the solvent vial must be added to the concentrate vial to produce a concentrate-solvent mixture with the intended concentration of 10&#160;mg/mL cabazitaxel</li>\n\n<li>Pharmacists should review worksheets that are used in the preparation of cabazitaxel to ensure that they correctly inform pharmacy staff to add the entire content of the solvent vial to the concentrate vial</li>\n\n<li>Please report suspected adverse reactions, including those related to medication error, occurring with cabazitaxel on a Yellow Card (<a href=\"http://www.mhra.gov.uk/yellowcard\">www.mhra.gov.uk/yellowcard</a>) &#160;</li>\n</ul>\n</div>\n\n<p><strong>Further information</strong></p>\n\n<p>Letter sent to healthcare professionals <a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON333631\">sent Oct 23, 2013</a></p>\n\n<p><em>Article citation: Drug Safety Update volume 7 issue 4, November 2013: A4.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2013-11-01", 
  "date_last_modified": "2013-11-18", 
  "_assets": [], 
  "_item_id": 49, 
  "summary": "Cabazitaxel is supplied as a vial of concentrate and a vial of solvent. The concentrate must first be diluted with the solvent supplied before adding to the infusion solution\n\nIt is essential that the entire contents of the solvent vial is added to the concentrate vial to produce a concentrate-solvent mixture with the intended concentration of 10 mg/mL cabazitaxel\n\nPharmacies should review worksheets used in the preparation of cabazitaxel to ensure that they inform pharmacy staff to add the entire contents of the solvent vial to the concentrate vial", 
  "body": "Article date: November 2013\n\nBackground\n\nCabazitaxel (Jevtana▼) in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.\n\nThere have been reports of medication error that have occurred because the entire fill volume of the solvent vial was not added to the concentrate vial. This has resulted in some patients receiving a higher dose (15–20% higher) of cabazitaxel than was intended.\n\nThe solvent vial and the concentrate vial each contain an overfill to compensate for liquid lost during the initial dilution process. Therefore, the entire contents of the solvent vial must be added to the concentrate vial to ensure that the resulting concentrate-solvent mixture contains the intended concentration of 10 mg/mL cabazitaxel and has a minimal extractable volume of 6 mL.\n\nThe required volume of the concentrate-solvent mixture should be diluted immediately (within 1 hour) to prepare the solution for infusion, as described in the [Summary of Product Characteristics](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002018/human_med_001428.jsp&mid=WC0b01ac058001d124), which should be consulted before preparing the cabazitaxel solution for infusion.\n\nAdvice for healthcare professionals:  \n  \n  * All healthcare professionals involved in the preparation of cabazitaxel solution for infusion should be aware that the entire contents of the solvent vial must be added to the concentrate vial to produce a concentrate-solvent mixture with the intended concentration of 10 mg/mL cabazitaxel  \n  * Pharmacists should review worksheets that are used in the preparation of cabazitaxel to ensure that they correctly inform pharmacy staff to add the entire content of the solvent vial to the concentrate vial  \n  * Please report suspected adverse reactions, including those related to medication error, occurring with cabazitaxel on a Yellow Card ([www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard))    \n  \nFurther information\n\nLetter sent to healthcare professionals [sent Oct 23, 2013](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON333631)\n\nArticle citation: Drug Safety Update volume 7 issue 4, November 2013: A4.\n"
}